Repligen Corporation
$ 136.44
2.87%
13 Feb - close price
- Market Cap 7,465,842,000 USD
- Current Price $ 136.44
- High / Low $ 140.75 / 133.39
- Stock P/E 4421.00
- Book Value 37.01
- EPS 0.03
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE N/A %
- 52 Week High 175.77
- 52 Week Low 102.97
About
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$190.89
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-11-12 | 2024-07-30 | 2024-05-01 | 2024-02-21 | 2023-10-31 | 2023-08-02 | 2023-05-02 | 2023-02-22 |
| Reported EPS | 0.46 | 0.37 | 0.39 | 0.44 | -0.0117 | 0.33 | 0.28 | 0.33 | 0.23 | 0.53 | 0.64 | 0.68 |
| Estimated EPS | 0.42 | 0.39 | 0.3668 | 0.4191 | 0.33 | 0.33 | 0.3 | 0.33 | 0.17 | 0.48 | 0.59 | 0.58 |
| Surprise | 0.04 | -0.02 | 0.0232 | 0.0209 | -0.3417 | 0 | -0.02 | 0 | 0.06 | 0.05 | 0.05 | 0.1 |
| Surprise Percentage | 9.5238% | -5.1282% | 6.325% | 4.9869% | -103.5455% | 0% | -6.6667% | 0% | 35.2941% | 10.4167% | 8.4746% | 17.2414% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGEN
2026-02-12 09:57:28
Repligen (NASDAQ:RGEN) is expected to release its Q4 2025 earnings before market open on Thursday, February 19th, with analysts anticipating earnings of $0.44 per share and revenue of $192.225 million. The company currently holds a "Moderate Buy" consensus rating from analysts, with insider selling activity noted over the past 90 days and significant institutional ownership. An earnings call is scheduled for February 24th to discuss the results.
2026-02-11 09:57:45
Repligen Corporation (NASDAQ:RGEN) announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will issue a press release before market open and host a conference call at 8:30 a.m. ET to discuss the results and business updates. Interested parties can access the call via a toll-free number or a webcast on the Investor Relations section of Repligen’s website.
2026-02-11 09:57:28
Repligen Corporation (NASDAQ:RGEN) announced it will report its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026. The company will issue a press release before market open and host a conference call at 8:30 a.m. ET to discuss the results and business updates for the period ended December 31, 2025. The conference call and webcast details for investors were also provided.
2026-02-10 12:58:41
Repligen Corporation announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and business updates. Repligen is a global life sciences company specializing in bioprocessing technologies for biological drug manufacturing.
2026-02-09 19:58:41
Azzad Asset Management Inc. ADV reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 60.7% in Q3, now holding 8,183 shares valued at approximately $1.09 million. Despite this, other institutions increased their positions, and Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $179.62. Company insiders have sold shares totaling $7.72 million in the last three months, while institutional investors own nearly 97.64% of the stock.
2026-02-08 10:28:09
Baron Health Care Fund recently added Repligen (RGEN) to its portfolio, citing the company's bioprocessing technology, AI for real-time drug production monitoring, and potential for growth from pharmaceutical reshoring. This endorsement reinforces Repligen's investment narrative as a key supplier to biopharma, though market sentiment suggests it may not be a major short-term driver. Investors are advised to consider various perspectives and risks, including valuation and execution, despite the fund's backing.
